Juisci Secures €5.5M Seed for AI HealthTech Expansion

\n Paris-based Juisci , a leading HealthTech company, has secured €5.5 million in Seed funding. Big Pi Ventures led the round.

1 min read
Juisci Secures €5.5M Seed for AI HealthTech Expansion

Paris-based Juisci, a leading HealthTech company, has secured €5.5 million in Seed funding. Big Pi Ventures led the round. This investment will boost Juisci's research and development efforts. Furthermore, it supports team scaling and accelerates international expansion, particularly into the U.S. market.

Robin Roumengas and Dr David Luu founded Juisci in 2021. This Juisci HealthTech solution democratizes access to scientific knowledge using proprietary AI and a mobile-first experience.

Related startups

Juisci aims to save professionals time.

Consequently, it advances medical progress by fighting misinformation.

Advancing Medical Knowledge Access

Juisci's platform transforms vast scientific data into actionable insights. Additionally, it provides digestible summaries, article recommendations, and multimedia content. Over 200,000 users in 60 countries currently leverage Juisci's tools. The Juisci HealthTech platform saves them up to eight hours weekly.

The company works with major pharmaceutical and MedTech firms, including Sanofi and Johnson & Johnson. Furthermore, Juisci addresses the challenge of exploding medical knowledge, which doubles every 73 days. Unlike traditional publishers like Elsevier or data platforms such as Tempus AI, Juisci offers an AI innovation for mobile-first access. This HealthTech startups funding round will fuel its global reach.

© 2025 StartupHub.ai. All rights reserved. Do not enter, scrape, copy, reproduce, or republish this article in whole or in part. Use as input to AI training, fine-tuning, retrieval-augmented generation, or any machine-learning system is prohibited without written license. Substantially-similar derivative works will be pursued to the fullest extent of applicable copyright, database, and computer-misuse laws. See our terms.